Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Drug company (FDA labeler)

Solco Healthcare LLC

NDC labeler code: 43547

What is a labeler?

The company whose name is on the package and in the FDA’s National Drug Code (NDC) Directory. It may make the medicine itself or sell medicine made by another company. The first part of every NDC code identifies the labeler.

Official FDA data only

Products, approvals and recalls come from the FDA (NDC Directory, Drugs@FDA, enforcement reports). Recalls are linked to this company by the NDC labeler code on the recalled product.

Questions about your medicine: ask your doctor or pharmacist. In an emergency, call 911.

At a glance

41Products (NDC)

Prescription medicines

FDA applications for these products

  • ANDA: Abbreviated New Drug Application: how a generic version is approved.
ApprovedApplicationMedicineSponsor
February 25, 2026ANDA220329 Hydrocortisone
HYDROCORTISONE
Appco
September 18, 2024ANDA212931 Bumetanide
BUMETANIDE
Appco
June 11, 2019ANDA209026 Potassium chloride
POTASSIUM CHLORIDE
Prinston
April 30, 2019ANDA209922 Potassium chloride
POTASSIUM CHLORIDE
Prinston
April 17, 2018ANDA207806 Pioglitazone
PIOGLITAZONE HYDROCHLORIDE
Prinston
April 11, 2018ANDA207455 Candesartan cilexetil and hydrochlorothiazide
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
Prinston
November 20, 2017ANDA209757 Clonidine
CLONIDINE HYDROCHLORIDE
Xiamen LP Pharm Co
November 6, 2017ANDA209028 Telmisartan and hydrochlorothiazide
TELMISARTAN AND HYDROCHLOROTHIAZIDE
Prinston
October 10, 2017ANDA208782 Entecavir
ENTECAVIR
Prinston
August 18, 2017ANDA207188 Paroxetine
PAROXETINE MESYLATE
Prinston
August 29, 2016ANDA205670 Fosinopril sodium
FOSINOPRIL SODIUM
Prinston
March 9, 2007ANDA077901 Clonidine
CLONIDINE HYDROCHLORIDE
Prinston
June 28, 2006ANDA077856 Clonazepam
CLONAZEPAM
Prinston
March 26, 2004ANDA076796 Furosemide
FUROSEMIDE
Prinston
July 1, 2002ANDA076230 Lisinopril and hydrochlorothiazide
LISINOPRIL AND HYDROCHLOROTHIAZIDE
Prinston Inc
October 29, 1979ANDA086988 Methocarbamol
METHOCARBAMOL
Prinston Inc

The sponsor is the company that holds the FDA application; it can differ from the labeler.

Recall timeline

2022

  1. January 26, 2022 · Class II · Terminated · D-0176-2024 · Donepezil hydrochloride

    CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

    Donepezil HCl Tablets, 10 mg, 90 Tablets, Rx only, Distributed by: Solco Healthcare U.S. LLC, Hurracao, Puerto Rico 00791. NDC: 43547-276-09

  2. January 26, 2022 · Class II · Terminated · D-0177-2024 · Donepezil hydrochloride

    CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

    Donepezil HCl Tablets, 5 mg, 90 Tablets, Rx only, Distributed by: Solco Healthcare U.S. LLC, Hurracao, Puerto Rico 00791. NDC: 43547-275-09

2019

  1. January 18, 2019 · Class II · Completed · D-0409-2019 · Irbesartan

    CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

    Irbesartan Tablets 300 mg 90 count Rx only Manufactured by: Zhejiang Huahai Pharmaceutical Co., Xunqiao, Linhai, Zhejiang 317024 China Distributed by: Solco Healthcare US, LLC Cranbury, NJ 08512 NDC 43547-376-09

  2. January 18, 2019 · Class II · Completed · D-0413-2019 · Irbesartan and hydrochlorothiazide

    CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

    Irbesartan and Hydrochlorothiazide Tablets, USP 150/12.5 mg Rx 30 Tablets Only Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd. Xunqiao, Linhai, Zheijang 317024, China Distributed by: Solco Healthcare US, LLC Cr

  3. January 18, 2019 · Class II · Completed · D-0410-2019 · Irbesartan and hydrochlorothiazide

    CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

    Irbesartan and HydrochlorothiazideTablets, USP 150/12.5 mg Rx Only 90 count Manufactured by: Zhejiang Huahai Pharmaceutical Co., Xunqiao, Linhai, Zhejiang 317024 China Distributed by: Solco Healthcare US, LLC Cranbury, N

  4. January 18, 2019 · Class II · Completed · D-0411-2019 · Irbesartan and hydrochlorothiazide

    CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

    Irbesartan and Hydrochlorothiazide Tablets, USP 300/12.5 mg Rx Only Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd. Xunqiao, Linhai, Zheijang 317024, China Distributed by: Solco Healthcare US, LLC Cranbury, NJ

  5. January 18, 2019 · Class II · Completed · D-0412-2019 · Irbesartan and hydrochlorothiazide

    CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

    Irbesartan and Hydrochlorothiazide Tablets, USP 300/12.5 mg Rx Only Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd. Xunqiao, Linhai, Zheijang 317024, China Distributed by: Solco Healthcare US, LLC Cranbury, NJ

2018

  1. July 13, 2018 · Class II · Ongoing · D-0971-2018 · Valsartan

    CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

    Solco Healthcare US Valsartan, USP, 320 MG Tablets, 90-count bottle,Rx Only Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd. Xynqiao, Linhai, Zhejiang 317024, China Distributed by: Solco Healthcare US, LLC Cranb

  2. July 13, 2018 · Class II · Ongoing · D-0969-2018 · Valsartan

    CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

    Solco Healthcare US Valsartan, USP, 80 MG Tablets, 90-count bottle, Rx Only Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd. Xynqiao, Linhai, Zhejiang 317024, China Distributed by: Solco Healthcare US, LLC Cranb

  3. July 13, 2018 · Class II · Ongoing · D-0970-2018 · Valsartan

    CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

    Solco Healthcare US Valsartan, USP, 160 MG Tablets, 90-count bottles, Rx Only Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd. Xynqiao, Linhai, Zhejiang 317024, China Distributed by: Solco Healthcare US, LLC Cra

Show the 8 older recalls

2018

  1. July 13, 2018 · Class II · Ongoing · D-0975-2018 · Valsartan and hydrochlorothiazide

    CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

    Solco Healthcare US Valsartan and Hydrochlorothiazide, USP, 320 MG/12.5 MG Tablets, 90-count bottle, Rx Only, Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd. Xynqiao, Linhai, Zhejiang 317024, China Distributed

  2. July 13, 2018 · Class II · Ongoing · D-0976-2018 · Valsartan and hydrochlorothiazide

    CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

    Solco Healthcare US Valsartan and Hydrochlorothiazide, USP, 320 MG/25 MG Tablets, 90-count bottles, Rx Only, Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd. Xynqiao, Linhai, Zhejiang 317024, China Distributed b

  3. July 13, 2018 · Class II · Ongoing · D-0968-2018 · Valsartan

    CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

    Solco Healthcare US Valsartan, USP, 40 MG Tablets, 30- count bottle, Rx Only, Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd. Xynqiao, Linhai, Zhejiang 317024, China Distributed by: Solco Healthcare US, LLC Cra

  4. July 13, 2018 · Class II · Ongoing · D-0973-2018 · Valsartan and hydrochlorothiazide

    CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

    Solco Healthcare US Valsartan and Hydrochlorothiazide, USP, 160 MG/12.5 MG Tablets, 90-count bottles, Rx Only, Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd. Xynqiao, Linhai, Zhejiang 317024, China Distributed

  5. July 13, 2018 · Class II · Ongoing · D-0974-2018 · Valsartan and hydrochlorothiazide

    CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

    Solco Healthcare US Valsartan and Hydrochlorothiazide, USP, 160 MG/25 MG Tablets, 90-count bottle, Rx Only, Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd. Xynqiao, Linhai, Zhejiang 317024, China Distributed by

  6. July 13, 2018 · Class II · Ongoing · D-0972-2018 · Valsartan and hydrochlorothiazide

    CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

    Solco Healthcare US Valsartan and Hydrochlorothiazide, USP, 80 MG/12.5 MG Tablets, 90-count bottles, Rx Only, Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd. Xynqiao, Linhai, Zhejiang 317024, China Distributed

2017

  1. November 29, 2017 · Class II · Terminated · D-0209-2018 · Valsartan

    Failed Tablet/Capsule Specifications: confirmed customer complaint of thicker and heavier tablets in bottle.

    Valsartan Tablets, USP, 160 mg, 90-count bottles, Rx Only, Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd, Xunqiao, Linhai, Zhejiang 317024, China; Distributed by: Solco Healthcare US, LLC, Cranbury, NJ 08512,

2016

  1. May 30, 2016 · Class III · Terminated · D-1049-2016 · Irbesartan and hydrochlorothiazide

    Labeling: Incorrect or Missing Lot and/or Exp Date: Incorrect lot number, 327B160012, appears on the case label, the correct lot number, 327B16002 appears on the immediate container.

    Irbesartan and Hydrochlorothiazide Tablets, USP, 300/12.5 mg, Rx only, Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd, Xunqiao, Linhai, Zhejiang 317024, China; Distributed by: Solco Healthcare U.S., LLC, Cranbu

What do the recall classes mean?

Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).

Sources

  1. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  2. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026

FDA Enforcement Report search → · Report an error →